Steve E. Kalloger
Steve E. Kalloger
Verified email at vch.ca
TitleCited byYear
Integrated genomic analyses of ovarian carcinoma
Cancer Genome Atlas Research Network
Nature 474 (7353), 609, 2011
39192011
Integrated genomic characterization of endometrial carcinoma
DA Levine, Cancer Genome Atlas Research Network
Nature 497 (7447), 67, 2013
20972013
ARID1A mutations in endometriosis-associated ovarian carcinomas
KC Wiegand, SP Shah, OM Al-Agha, Y Zhao, K Tse, T Zeng, J Senz, ...
New England Journal of Medicine 363 (16), 1532-1543, 2010
12882010
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies
M Köbel, SE Kalloger, N Boyd, S McKinney, E Mehl, C Palmer, S Leung, ...
PLoS medicine 5 (12), e232, 2008
7112008
Mutation of FOXL2 in granulosa-cell tumors of the ovary
SP Shah, M Köbel, J Senz, RD Morin, BA Clarke, KC Wiegand, G Leung, ...
New England Journal of Medicine 360 (26), 2719-2729, 2009
5572009
Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers
A Heravi-Moussavi, MS Anglesio, SWG Cheng, J Senz, W Yang, ...
New England Journal of Medicine 366 (3), 234-242, 2012
3282012
Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer
Y Guan, WL Kuo, JL Stilwell, H Takano, AV Lapuk, J Fridlyand, JH Mao, ...
Clinical cancer research 13 (19), 5745-5755, 2007
3052007
Distinct evolutionary trajectories of primary high‐grade serous ovarian cancers revealed through spatial mutational profiling
A Bashashati, G Ha, A Tone, J Ding, LM Prentice, A Roth, J Rosner, ...
The Journal of pathology 231 (1), 21-34, 2013
2992013
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
JZ Press, A De Luca, N Boyd, S Young, A Troussard, Y Ridge, P Kaurah, ...
BMC cancer 8 (1), 17, 2008
2962008
Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors
K Milne, M Köbel, SE Kalloger, RO Barnes, D Gao, CB Gilks, PH Watson, ...
PloS one 4 (7), e6412, 2009
2752009
Differences in tumor type in low-stage versus high-stage ovarian carcinomas
M Köbel, SE Kalloger, DG Huntsman, JL Santos, KD Swenerton, ...
International Journal of Gynecological Pathology 29 (3), 203-211, 2010
2602010
Quantitative assessment of airway remodeling using high-resolution CT
Y Nakano, NL Müller, GG King, A Niimi, SE Kalloger, M Mishima, PD Paré
Chest 122 (6), 271S-275S, 2002
2442002
Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell–and patient-derived tumor organoids
L Huang, A Holtzinger, I Jagan, M BeGora, I Lohse, N Ngai, C Nostro, ...
Nature medicine 21 (11), 1364, 2015
2352015
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss
B Clarke, AV Tinker, CH Lee, S Subramanian, M Van De Rijn, D Turbin, ...
Modern Pathology 22 (3), 393, 2009
2232009
Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma
CB Gilks, DN Ionescu, SE Kalloger, M Köbel, J Irving, B Clarke, J Santos, ...
Human pathology 39 (8), 1239-1251, 2008
2232008
A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary
M Köbel, SE Kalloger, J Carrick, D Huntsman, H Asad, E Oliva, ...
The American journal of surgical pathology 33 (1), 14-21, 2009
1992009
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer
MS Anglesio, J George, H Kulbe, M Friedlander, D Rischin, C Lemech, ...
Clinical cancer research 17 (8), 2538-2548, 2011
1942011
Loss of BAF250a (ARID1A) is frequent in high‐grade endometrial carcinomas
KC Wiegand, AF Lee, OM Al‐Agha, C Chow, SE Kalloger, DW Scott, ...
The Journal of pathology 224 (3), 328-333, 2011
1822011
Genotypic and Phenotypic Diversity of phlD-ContainingPseudomonas Strains Isolated from the Rhizosphere of Wheat
BBMS Gardener, KL Schroeder, SE Kalloger, JM Raaijmakers, ...
Appl. Environ. Microbiol. 66 (5), 1939-1946, 2000
1722000
HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy
JN McAlpine, KC Wiegand, R Vang, BM Ronnett, A Adamiak, M Köbel, ...
BMC cancer 9 (1), 433, 2009
1662009
The system can't perform the operation now. Try again later.
Articles 1–20